- Home
- CRL
CRL
Charles River Laboratories International Inc.
as 02-04-2025 4:00pm EST
| Founded: | 1947 | Country: | United States |
| Employees: | N/A | City: | WILMINGTON |
| Market Cap: | N/A | IPO Year: | 2000 |
| Target Price: | $201.92 | AVG Volume (30 days): | 974.9K |
| Analyst Decision: | Hold | Number of Analysts: | 15 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 8.00 | EPS Growth: | -13.25 |
| 52 Week Low/High: | $159.65 - $275.00 | Next Earning Date: | 02-19-2025 |
| Revenue: | $4,060,916,000 | Revenue Growth: | -3.67% |
| Revenue Growth (this year): | -1.37% | Revenue Growth (next year): | -0.27% |
Latest Charles River Laboratories International Inc. News
CRL Breaking Stock News: Dive into CRL Ticker-Specific Updates for Smart Investing
Zacks
2 days ago
CRL Gears Up for Q4 Earnings: Here's What You Need to Know
Business Wire
8 days ago
Charles River Laboratories Schedules Fourth-Quarter 2024 Earnings and 2025 Guidance Release and Conference Call
MT Newswires
13 days ago
Goldman Sachs Adjusts Charles River Laboratories International Price Target to $190 From $220, Maintains Buy Rating
TipRanks
13 days ago
Charles River downgraded to Market Perform from Outperform at William Blair
Zacks
14 days ago
Charles River Launches Apollo for CRADL to Boost Research, Stock Rises
MT Newswires
14 days ago
William Blair Downgrades Charles River Laboratories International to Market Perform From Outperform
MT Newswires
15 days ago
TD Cowen Adjusts Charles River Laboratories International Price Target to $182 From $227
Insider Monkey
15 days ago
RiverWater Partners Sustainable Value Strategy Trimmed its Investment in Charles River Laboratories (CRL)
Compare CRL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CRL Charles River Laboratories International Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.